Drug Profile
Research programme: osteoblast stimulant - Skelegen
Latest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator University of Pennsylvania
- Developer Skelegen
- Class Proteins
- Mechanism of Action Notch receptor modulators; Osteoblast stimulants; Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Spinal disorders
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for research development in Spinal-disorders in USA (Intralesional, Implant)